Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fresh Challenge To EMA's Access To Documents Policy Raises Hopes For Clarity

Executive Summary

As the European Medicines Agency's policy on access to documents faces yet another legal challenge, the European Confederation of Pharmaceutical Entrepreneurs is hoping the verdict will demystify what constitutes commercially confidential information in a marketing authorization application.

You may also be interested in...



Boost For Transparency As EU Court Backs EMA's Approach To Disclosing Clinical Data

The EU General Court has dismissed three cases by pharmaceutical companies that wanted to prevent the European Medicines Agency from disclosing certain data about their marketed medicines on the grounds that it would harm their commercial interests. Firms now have a clearer idea of the standards they will need to meet to claim their information is commercially confidential.

Greater Civil Society Involvement in Drug Evaluation Will Bring Challenges, Warns EMA Deputy Head

The European Medicines Agency is keen to highlight its landmark policy on proactive publication of clinical data but it’s aware of the challenges involved in this and other transparency initiatives.

EMA Appeals Interim EU Court Orders Preventing Access To Documents

The European Medicines Agency is looking for a clear indication from the EU courts on whether its approach to transparency – as defined in its access to documents policy – is correct.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS119124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel